<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461772</url>
  </required_header>
  <id_info>
    <org_study_id>CCRTCICA-CXCA</org_study_id>
    <nct_id>NCT01461772</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer</brief_title>
  <official_title>Comparison of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Concurrent Chemoradiation Therapy With Weekly Carboplatin in Locally Advanced Cervical Cancer: Phase III Multicenter Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concurrent chemoradiation therapy with weekly cisplatin is the current standard treatment
      for patients with locally advanced cervical cancer. However, weekly cisplatin is related to
      renal toxicity and not convenient regimen. Recently, carboplatin has proved to be a good
      radiosensitizer and less renal toxicity. Weekly carboplatin is more convenient regimen for
      both patients and physicians. Weekly carboplatin may have similar efficacy with weekly
      cisplatin and may have more favorable toxicity profile. Therefore, the investigators aimed
      to evaluate the efficacy and safety of concurrent chemoradiation with weekly carboplatin in
      patients with locally advanced cervical cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 months after completion of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Before each chemotherapy, an average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>CCRT weekly carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiation therapy with weekly carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRT weekly cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemoradiation therapy with weekly cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)</description>
    <arm_group_label>CCRT weekly carboplatin</arm_group_label>
    <arm_group_label>CCRT weekly cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36</description>
    <arm_group_label>CCRT weekly carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36</description>
    <arm_group_label>CCRT weekly cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated, histologically confirmed cervical cancer

          -  One of following histologic types Squamous carcinoma, adenocarcinoma, adenosquamous
             carcinoma

          -  Age: 20-75 years

          -  GOG performance status: 0-2

          -  Adequate organ function Bone marrow: WBC ≥ 3,000/mm3, ANC ≥ 1,500/mm3, Platelet ≥
             100X103/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine &lt; 1.25 × UNL, Liver : AST, ALT &lt; 3 ×
             UNL, T- bilirubin &lt; 1.5 mg/ mm3

          -  Contraception during study treatment

          -  Informed consent

        Exclusion Criteria:

          -  Previous chemotherapy or pelvic radiation therapy

          -  Hormone therapy within 4 weeks

          -  Concomitant malignancy within 5 years except cured basal cell carcinoma of skin

          -  Uncontrolled medical disease

          -  Pregnant or lactating woman

          -  Etc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <phone>+82-2-3010-3633</phone>
    <email>jhnam@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
    <phone>+82-2-3010-3646</phone>
    <email>obgyjypark@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
      <phone>+82-2-3010-3633</phone>
      <email>jhnam@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 27, 2011</lastchanged_date>
  <firstreceived_date>October 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Hyun Nam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
